Literature DB >> 3517331

1H NMR configurational correlation for retro-inverso dipeptides: application to the determination of the absolute configuration of "enkephalinase" inhibitors. Relationships between stereochemistry and enzyme recognition.

M C Fournié-Zaluski, E Lucas-Soroca, J Devin, B P Roques.   

Abstract

A stereospecific synthesis of thiorphan [N-[2(RS)-(mercaptomethyl)-1-oxo-3-phenylpropyl]glycine] and retro-thiorphan [3-[[1(RS)-(mercaptomethyl)-2-phenylethyl]amino]-3-oxopropanoic acid], two highly potent inhibitors of enkephalinase, a neutral endopeptidase involved in enkephalin metabolism, is reported. Due to a rapid isomerization process, derivatives of retro-thiorphan, which contains a 2-substituted malonyl moiety, cannot be separated by classical methods. However, a separation of the diastereoisomeric mixtures of these retro-thiorphan derivatives was achieved by HPLC. The absolute configuration of each isomer was determined by using an NMR configurational correlation. The inhibitory potency of the various inhibitors indicates that, in the thiorphan series, the affinity for enkephalinase is independent of the stereochemistry of the 2-(mercaptomethyl)-1-oxo-3-phenylpropyl moiety. In contrast, in the retro-thiorphan series a 100-fold difference in the inhibitory activity of the two enantiomers is observed. This indicates that there are large differences in the conformational behavior of the two series of inhibitors at the active site of the enzyme.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3517331     DOI: 10.1021/jm00155a027

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  7 in total

1.  Aminophosphinic inhibitors as transition state analogues of enkephalin-degrading enzymes: a class of central analgesics.

Authors:  H Chen; F Noble; P Coric; M C Fournie-Zaluski; B P Roques
Journal:  Proc Natl Acad Sci U S A       Date:  1998-09-29       Impact factor: 11.205

2.  Dual inhibition of angiotensin-converting enzyme and neutral endopeptidase by the orally active inhibitor mixanpril: a potential therapeutic approach in hypertension.

Authors:  M C Fournié-Zaluski; W Gonzalez; S Turcaud; I Pham; B P Roques; J B Michel
Journal:  Proc Natl Acad Sci U S A       Date:  1994-04-26       Impact factor: 11.205

3.  Mixed inhibitors of angiotensin-converting enzyme (EC 3.4.15.1) and enkephalinase (EC 3.4.24.11): rational design, properties, and potential cardiovascular applications of glycopril and alatriopril.

Authors:  C Gros; N Noël; A Souque; J C Schwartz; D Danvy; J C Plaquevent; L Duhamel; P Duhamel; J M Lecomte; J Bralet
Journal:  Proc Natl Acad Sci U S A       Date:  1991-05-15       Impact factor: 11.205

4.  Design of the first highly potent and selective aminopeptidase N (EC 3.4.11.2) inhibitor.

Authors:  H Chen; B P Roques; M C Fournié-Zaluski
Journal:  Bioorg Med Chem Lett       Date:  1999-06-07       Impact factor: 2.823

5.  Synthesis, high-throughput screening and pharmacological characterization of β-lactam derivatives as TRPM8 antagonists.

Authors:  Roberto de la Torre-Martínez; M Angeles Bonache; Pedro J Llabrés-Campaner; Beatriz Balsera; Asia Fernández-Carvajal; Gregorio Fernández-Ballester; Antonio Ferrer-Montiel; M Jesús Pérez de Vega; Rosario González-Muñiz
Journal:  Sci Rep       Date:  2017-09-07       Impact factor: 4.379

6.  Hepatoprotective Principles and Other Chemical Constituents from the Mycelium of Phellinus linteus.

Authors:  Shiow-Chyn Huang; Pei-Wen Wang; Ping-Chung Kuo; Hsin-Yi Hung; Tai-Long Pan
Journal:  Molecules       Date:  2018-07-12       Impact factor: 4.411

7.  Highly functionalized β-lactams and 2-ketopiperazines as TRPM8 antagonists with antiallodynic activity.

Authors:  M Ángeles Bonache; Cristina Martín-Escura; Roberto de la Torre Martínez; Alicia Medina; Sara González-Rodríguez; Andrés Francesch; Carmen Cuevas; Ana María Roa; Gregorio Fernández-Ballester; Antonio Ferrer-Montiel; Asia Fernández-Carvajal; Rosario González-Muñiz
Journal:  Sci Rep       Date:  2020-08-25       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.